Atom Investors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Atom Investors’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-11,388	Closed	-$35K	–	395
2022 Q2	$35K	Sell	11,388 -60,544	-84%	-$294K	0.02%	238
2022 Q1	$488K	Sell	71,932 -4,707	-6%	-$33.5K	0.23%	102
2021 Q4	$640K	Buy	+76,639	New	+$631K	0.11%	142
2021 Q2	–	Sell	-54,762	Closed	-$562K	–	363
2021 Q1	$562K	Buy	+54,762	New	+$600K	0.09%	147

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Atom Investors's JNCE Position: Q3 2022 in Review

Atom Investors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2022, closing a stake of 11,388 shares — an estimated $35K sold.

Atom Investors first reported a position in JNCE in Q1 2021 and held it in 4 quarters. The position peaked at $640K in Q4 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

Atom Investors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Atom Investors sold 11,388 Jounce Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $35K.
Atom Investors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
Atom Investors's Jounce Therapeutics, Inc. Common Stock position peaked at $640K in Q4 2021.
102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Atom Investors's 13F filing for Q3 2022, filed 8 Nov 2022.